

BBBIOTECH

BB BIOTECH AG

Press Release January 28, 2009

BB BIOTECH completes fifth share buy-back program

On January 28, 2009, BB BIOTECH AG completed its fifth share buy-back program, which commenced on April 4, 2008. During that period, 2 025 000 registered shares were redeemed via a second trading line. The Board of Directors will propose to the Annual General Meeting on March 30, 2009 that the 2 025 000 registered shares be cancelled, in order to complete the capital decrease.

For further information, please contact:

Bellevue Asset Management AG, Seestrasse 16, CH-8700 Küsnacht/Zurich
Anja Stubenrauch, phone +41 44 267 67 00

Company profile:

BB BIOTECH acquires holdings in companies in the biotechnology growth market and is currently one of the world's largest investors in the sector. BB BIOTECH is listed in Switzerland, in Germany and in Italy. The focus of the holdings is on quoted companies that are concentrating on the development and marketing of innovative medicines. For the selection of holdings, BB BIOTECH relies on fundamental analysis by physicians and molecular biologists. The Board of Directors has many years of industrial and scientific experience.